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Abstract: We investigated the effect of magnetic nanoparticles of Fe3O4 (Fe3O4-MNPs) on 
the mice immune system. Imprinting control region (ICR) mice were assigned randomly into 
four groups and treated with normal saline or low, medium, or high doses of Fe3O4-MNPs, 
respectively. After intravenous administration of Fe3O4-MNPs for 72 hours, the peripheral T cells 
and the induction of primary immune responses in mice were investigated by flow cytometry 
and determined using enzyme-linked immunosorbent assay, respectively. The results showed 
that the ratio of spleen to body weight was not different between the experimental groups and 
control group (P . 0.05). The lymphocyte transformation rates in the suspension of spleen were 
higher in low-dose group than those in the control group (P , 0.05), while the proliferation 
of splenocytes was low in the medium and high groups when compared to the control group 
(P , 0.05). In peripheral blood, both the proportions of subset CD4+ and CD8+ T lymphocytes in 
the low-dose group were higher than those in the control group, whereas there was no difference 
in the number of CD4+ T cells between the medium- and low-dose groups. Interestingly, the 
Fe3O4-MNPs enhanced the production of interleukin-2 (IL-2), interferon-γ, and IL-10 but did 
not affect the production of IL-4 in peripheral blood. It is concluded that Fe3O4-MNPs could 
influence immune functions of normal ICR mice in a dose-dependent manner.
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Nanotechnology offers an efficient alternative for cancer diagnostics and tumor target 
treatment due to the unique properties of nanostructures, such as large surface-to-volume 
ratio, porous structure, embedded effect, and size effect, which have been recognized as 
offering potential promising applications in biomedical engineering. Much effort has 
been extended to the development of novel nanocomposites and   biomaterials for DNA 
detection,1 intracellular labeling,2 drug carrier,3 cancer targeting,4 imaging,5 and so on. 
Therefore, magnetic nanoparticles of Fe3O4 (Fe3O4-MNPs) as a kind of   biocompatible 
  nanomaterial which is feasible to characterize and easily   functionalize, may offer an excit-
ing   development toward developing an effective drug delivery system while biocompatible 
superparamagnetic particles like magnetite could be utilized in tissue-specific release of 
therapeutic agents and magnetic field assisted radionuclide therapy.6–9
As a novel material, though we have already proved that Fe3O4-MNPs have no 
cytotoxicity, the exact function of Fe3O4-MNPs on immune function has not yet been 
adequately clarified. In the present paper, we investigated the effects of Fe3O4-MNPs 
on the immune system in imprinting control region (ICR) mice to elucidate the inter-
actions between Fe3O4-MNPs and immune system and to provide theoretic evidence 
for the clinical applications.International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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Materials and methods
experimental agents
Experimental agents were sourced from the following 
  locations: RPMI1640 (Gibco Chemical Co., Carlsbad, 
CA, USA); Anti-CD3 (PE-Cy5), Anti-CD4, Anti-CD8 
(  Pharmingen, San Diego, CA); Calf serum (Gibco Chemical 
Co); Enzyme-linked immunosorbent assay kit (Gibco, CA, 
USA); Con A (Sigma Chemical Co., St Louis, MO, USA).
Preparation of Fe3O4-MNPs
Based on our previous studies,10–11 the synthesis of Fe3O4-MNPs 
was prepared by the electrochemical deposition under oxidizing 
conditions. Before being applied in the present experiment, the 
magnetite nanoparticles were well-distributed in RPMI-1640 
medium freshly added with 10% heated-inactivated fetal 
bovine serum (FBS) using ultrasound treatment in order to 
obtain Fe3O4-MNPs colloidal suspension.
Animals and animal care
Female and male ICR mice, which were age-matched 
(eight weeks of age) and weight-matched (18–22 g), were 
purchased from Shanghai National Center for Laboratory 
Animals. Animals were kept with a 12-hour light/dark cycle 
and received water and food ad libitumina semi-barrier 
system. The experiments were performed in adherence to 
the guidelines for the Care and Use of Laboratory Animals 
of the National Institute of Health.
experimental groups and preparation  
for blood samples
Mice were randomly assigned to one of four groups (n = 10 
per group). The doses of 5.14 mg/kg (low dose group), 
20.7 mg/kg (medium dose group), and 51.4 mg/kg (high dose 
group) Fe3O4-MNPs, were dissolved in normal saline and 
intravenously (iv) injected into mice once. Meanwhile, those 
injected with 0.2 mL normal saline alone formed the control 
group. After being monitored for 72 hours, the eyeballs of 
mice were extirpated for blood collecting at the end of this 
period and spleens were aseptically removed immediately, 
blotted, and weighed and then used for various analyses. 
Blood samples obtained from the mice were centrifuged 
(1500 rpm) for 5 minutes at 4°C to separate plasma and 
blood cells. The blood cells were used for analyzing surface 
markers of lymphocytes and the plasma was stored at −80°C 
for determination of cytokines.
Lymphocyte proliferation assay
Single-cell suspensions were prepared from the spleens in 
RPMI-1640 medium. Briefly, a cell suspension was produced 
by puncturing the spleen with a 20-gauge needle gently 
  flushing the organ with ice-cooled (4°C) culture medium solu-
tion. The suspension was freed from debris by centrifugation 
at 1000 rpm for 20 minutes at 4°C. And the remaining 
splenocyte suspensions were washed twice and adjusted 
to 2 × 106 cells/mL with RPMI-1640. The splenocyte cell 
suspension was placed in a 96-well microtiter plate in 200 µL 
aliquots, and cultured in the presence or absence of T-cell 
mitogen (concanavalin A [ConA], Sigma, USA) (5 µg/mL). 
Meanwhile the wells receiving complete RPMI-1640 were 
regarded as control. Cells were cultured for 68 hours at 37°C 
in a 5% humidified CO2 atmosphere, following which 10 µL 
MTT (0.5 mg/mL) were added to each well at 37°C in the 
dark for at least 4 hours, the formazan crystals were dissolved 
in 150 µL dimethyl sulfoxide (Sigma Aldrich) and the reduc-
tion of MTT was quantified by absorbance at a wavelength of 
570 nm using a microplate reader (Model-550; Bio-Rad Lab-
oratories, Hercules, CA, USA). The results were expressed as 
a mean differential optical density (ODmitogen-ODcontrol).
The proportions of lymphocyte subset
Phenotypic analyses of blood lymphocytes were performed 
using FCM. Briefly, the cells were incubated with PE 
or FITC-conjugated monoclonal antibodies [Anti-CD3 
(PE-Cy5), Anti-CD4 (FITC), or Anti-CD8 (PE)] for 
10   minutes, washed three times, and then resuspended in 
FACS permeabilizing solution before determination. At least 
10,000 cells were analyzed for each MoAb staining using a 
FACScan flow cytometer (Becton Dickinson, Franklin Lakes, 
NJ, USA). Results were expressed as mean fluorescence 
intensity for a given molecule per cell.
Assessment of cytokines
The levels of interleukin-2 (IL-2), interleukin-4 (IL-4), 
  interleukin-10 (IL-10), and interferon-γ (INF-γ) in serum were 
  measured in duplicate using enzyme-linked immunosorbent 
assay kit according to the manufacturer’s instruction. Briefly, 
50 µL samples or standard control were added to 50 µL assay 
diluents for each well, incubated at room temperature for 2 hours; 
after thorough washing, 100 µL conjugate was added to each 
well for incubation of 2 hours. Then 100 µL substrate solution 
was added to each well and incubated for 30 minutes. Finally, a 
100 µL stop solution was added to each well and the optical den-
sity was measured using ELISA reader (Bio-Rad Laboratories, 
Hercules, CA, USA) with dual wavelength of 450 nm.
statistical analysis
Data were analyzed using the Statistical Package for Social 
Science (version 13.0; SPSS Inc., Chicago, IL, USA). The International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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significant difference between groups was analyzed using 
one-way ANOVA; P values ,0.05 were considered statisti-
cally significant.
Results
The characteristic of Fe3O4-MNPs
A colloidal suspension of Fe3O4-MNPs was achieved by 
using ultrasound treatment and the magnetization and the 
size of Fe3O4-MNPs were found to be 25.6 × 10−3 emu/mg 
and 20 nm, respectively (Figure 1).
The changes of spleen weight in Fe3O4-
MNPs-treated ICr mice
Mice treated with Fe3O4-MNPs appeared healthy and their 
body weight gain patterns were similar to controls (data not 
included). The spleens of Fe3O4-MNPs-treated mice showed 
same appearance as the controls. Both the spleen weight 
and the ratio of spleen weight to body weight showed no 
significant difference between the experimental groups and 
the controls (Table 1). It suggested that Fe3O4-MNPs did 
not cause splenomegaly, which was due to the deposition of 
damaged erythrocytes or to recruitment and/or proliferation 
of splenic cells.
splenocyte proliferation
A significant increase of splenocyte proliferative capacity 
was noticed after administration of Fe3O4-MNPs in low dose 
(P , 0.05; low dose versus control). Both administration of 
medium-dose and high-dose Fe3O4-MNPs affect   splenocyte 
proliferation and reduced the splenocyte proliferative   capacity 
compared with the control group (P , 0.05; control versus 
medium-dose/high-dose Fe3O4-MNPs) (Table 2).12
The proportions of lymphocyte subsets 
in peripheral blood
There were no differences between the low-dose group and 
the medium-dose group in the proportions of CD4+ T-cell 
subset in peripheral blood of ICR mice, and both had more 
CD4+ T lymphocytes than the control group. But the high-
dose group showed no difference compared with control 
(P . 0.05) (Figures 2 and 3). Furthermore the proportions of 
CD8+ T lymphocytes subset were slightly lower after the com-
mencement of high dose. Though both low- and medium-dose 
groups indicated that they have more CD8+ T lymphocytes 
than those of control group, and the low-dose group showed 
significantly more when compared to the medium-dose group 
(P , 0.05) (Figures 4 and 5).
Cytokine release
To detect whether Fe3O4-MNPs can alter cytokine production 
patterns in peripheral blood, enzyme-linked immunosorbent 
assay was conducted. Fe3O4-MNPs altered the production 
of IL-2, INF-γ, and IL-10. Interestingly, low dose of 
Fe3O4-MNPs significantly increased the levels of IFN-γ, 
IL-2, IL-10 and IL-4 (P , 0.05) when compared to medium 
or high doses of Fe3O4-MNPs (P , 0.05), and there were 
no significant differences between medium and high doses 
of Fe3O4-MNPs (P . 0.05), suggesting that low dose of 
Fe3O4-MNPs significantly increased the ability of splenocytes 
to release cytokines. But no significant changes of IL-4 were 
observed between the experiment groups and the control 
group (Figure 6).
Discussion
Close attention has been paid to current nanoparticle 
techniques. It is well known that nanoparticles could present 
a versatile nanoscale surface for biomolecular recognition 
because of the numerous potential benefits in merging 
biomacromolecules and nanoparticles. Meanwhile, much 
effort has been explored to the development of new nano-
composites and their application in many research fields 
such as DNA detection, intracellular labeling, drug carrier, 
and so on.
The magnetic nanoparticle of Fe3O4 we tested has good 
biocompatibility and no cytotoxicity.13,14 Our group have 
proved that Fe3O4-MNPs could increase the intracellular 
effective concentration of chemotherapeutic drugs in vitro 
to reverse MDR. The focus of this study was to investigate 
whether Fe3O4-MNPs have effects on mice immune 
system, especially the T cell functions after given different   
dose.
Figure 1 TeM Image of magnetic nanoparticles of Fe3O4, Bar = 20 nm (X40000 
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The total body weights of mice were not changed 
significantly, and the spleen/body weight ratio was 
unchanged. Actually, quantification of body weight and 
organ weight forms an integral part of any toxicological 
study   providing an initial assessment of overall animal health 
status, as well as potential pathology. Descriptions of the tier 
approach to immunotoxicity evaluation should incorporate 
  measurements of body weight, weights of spleen, thymus, 
kidney, and liver, as well as organ/body weight ratios in an 
initial screen.15
Proliferation of lymphocytes following exposure to 
mitogenic stimuli is an important methodology for the 
assessment of cell-mediated immunity. This assay has 
enjoyed frequent use in immunotoxicology studies for 
its ease of performance and relative reproducibility.16 
Therefore, we have   investigated the effects of Fe3O4-MNPs 
on lymphoproliferatior in spleen following exposure 
to Con-A. The results showed that the proliferation of 
lymphocytes was significantly increased when mice were 
injected with 5.14 mg/kg Fe3O4-MNPs compared with the 
controls. However, the other two groups did not act in a 
similar way.
To detect the levels of proportion of CD4+ or CD8+ T cells, 
which are markers for T cell lymphocytes. Fe3O4-MNPs 
influenced the function of helper T cells or suppresser T cells, 
when the less the Fe3O4-MNPs were given, the more of an 
increase in T cell numbers was seen, suggesting that low 
concentration of Fe3O4-MNPs can regulate T cell   functions 
in ICR mice.
The Th1 cytokines promote cellular immunity by activating 
macrophages, cytotoxic CD8+ T lymphocytes, and so on, 
while the Th2 cytokines enhance humoral immunity, 
including activation and class switching of antibody 
producing B cells.17 Th1 cells are defined by their ability to 
secrete the inflammatory cytokines IL-2 and INF-γ and are 
involved in cellular immunity, some autoimmune disease, 
and in chronic inflammatory disorders. The Th2-biased 
cells preferentially produce IL-4, IL-5, IL-10, and IL-13 
and participate in humoral response and antibody produc-
tion.18 In the present study, low dose of Fe3O4-MNPs was 
found to strongly affect the production of Th1 cytokine, 
and also affect some Th2 cytokine release, suggesting that 
Fe3O4-MNPs might be involved in inflammations associated 
with infections.
Conclusion
In conclusion, our results indicate Fe3O4-MNPs can influence 
immune functions of mice in a dose-dependent manner. 
Further study indicated that a high dose of Fe3O4-MNPs 
has no significant influence on the immune systems of the 
mice. These data could be useful for improving   biomedical 
  applications of Fe3O4-MNPs, but these immunological effects 
of Fe3O4-MNPs should be further conducted both in vivo 
and in vitro.
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Table 1 effects of Fe3O4-MNPs on the spleen weight and the ratio of spleen weight to body weight (n = 10, mean ± sD)
Groups Spleen weight (g) The ratio of spleen weight   
to body weight (×10-3)
Control (saline) 0.0940 ± 0.0152 3.3102 ± 0.4478
Low dose of Fe3O4-MNPs (5.14 mg/kg) 0.0720 ± 0.0286 2.3793 ± 0.8027*
Medium dose of Fe3O4-MNPs (20.7 mg/kg) 0.0900 ± 0.0187 3.1488 ± 0.5225*
high dose of Fe3O4-MNPs (51.4 mg/kg) 0.1120 ± 0.0084 4.0481 ± 0.8744*
Note: *P . 0.05, when compared to the control.
Table 2 Influence of Fe3O4-MNPs on the rate of lymphocyte 
transformation in spleen suspension (n = 10, mean ± sD)
Groups The rate of lymphocyte   
transformation 
Control (saline) 0.0193 ± 0.001027
Low dose of Fe3O4-MNPs (5.14 mg/kg) 0.0398 ± 0.005155*
Medium dose of Fe3O4-MNPs (20.7 mg/kg) 0.0111 ± 0.003029*
high dose of Fe3O4-MNPs (51.4 mg/kg) 0.0046 ± 0.001517*
Note: *P , 0.05, when compared to the control.International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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